Drug intelligence / Profile preview

diphenhydramine + zolpidem

Development stage
Phase 3
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Topical, Rectal
01

Overview

Di **Diphenhydramine + zolpidem** is a combination of two pharmaceutical drugs: diphenhydramine and zolpidem. Diphenhydramine is a first-generation H1 receptor antagonist (antihistamine) primarily used for treating allergies and as an over-the-counter sleep aid due to its sedative properties. Zolpidem is a non-benzodiazepine hypnotic that acts as a GABA-A receptor agonist and is FDA approved for the short-term treatment of insomnia. When combined, these drugs significantly increase central nervous system depression, leading to enhanced sedation, dizziness, and risk of confusion, especially in older adults. No unique branded combination exists under this name; their co-administration is generally discouraged due to a high risk of adverse effects[1][2][4].

Other names
diphenhydramine / zolpidem
02

Targets

GABRR (GABA-A receptor subunit rho)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)

Beyond the preview

Go deeper on diphenhydramine + zolpidem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphenhydramine + zolpidem.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call